HCA
FDMT icon

Harbor Capital Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Harbor Capital Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,716
Closed -$223K – 1318
2025
Q4 		$223K Buy
29,716
+17,815
+150% +$181K 0.02% 602
2025
Q3 		$103K Sell
11,901
-13,310
-53% -$79.5K 0.01% 660
2025
Q2 		$94K Sell
25,211
-5,384
-18% -$18.9K ﹤0.01% 651
2025
Q1 		$99K Buy
+30,595
New +$144K ﹤0.01% 660

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Harbor Capital Advisors's FDMT Position: Q1 2026 in Review

Harbor Capital Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 29,716 shares — an estimated $223K sold.

Harbor Capital Advisors first reported a position in FDMT in Q1 2025 and held it in 4 quarters. The position peaked at $223K in Q4 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Harbor Capital Advisors reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Harbor Capital Advisors sold 29,716 4D Molecular Therapeutics shares in Q1 2026, an estimated $223K.
  • Harbor Capital Advisors first reported a position in 4D Molecular Therapeutics in Q1 2025 and held it in 4 quarters.
  • Harbor Capital Advisors's 4D Molecular Therapeutics position peaked at $223K in Q4 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.